Back to top
more

Cardiff Oncology (CRDF)

(Delayed Data from NSDQ)

$3.48 USD

3.48
341,898

+0.09 (2.65%)

Updated May 13, 2024 04:00 PM ET

After-Market: $3.49 +0.01 (0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of 21.24% and 9.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 0.00% and 43.33%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Cardiff Oncology (CRDF) Report Negative Q3 Earnings? What You Should Know

Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardiff Oncology (CRDF) Stock Jumps 7%: Will It Continue to Soar?

Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -13.33% and 4.62%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Debanjana Dey headshot

Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on

Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.

Are Options Traders Betting on a Big Move in Cardiff Oncology (CRDF) Stock?

Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.

Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 0.00% and -4.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Cardiff Oncology (CRDF): Can Its 10.3% Jump Turn into More Strength?

Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sanghamitra Saha headshot

Rising P/E: An Overlooked Way to Pick 5 Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Sanghamitra Saha headshot

Rising P/E: An Overlooked Strategy to Pick Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Cardiff Oncology (CRDF) Stock Jumps 11.3%: Will It Continue to Soar?

Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Cardiff Oncology (CRDF) Stock Options

Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.

Implied Volatility Surging for Cardiff Oncology (CRDF) Stock Options

Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.